-
Modi vows punishment for exam fraud fuelling India protests
-
ASEAN to call for open straits as US-Iran war casts shadow
-
Six candidates in race to lead UN set for televised debate
-
AI catches up with humans to score 100% at top maths contest
-
Comic-Con kicks off with Marvel's return
-
South Korea election office raided in fake turnout figures probe: investigators
-
Dutch riders dreaming of crazy party corner of Alpe d'Huez
-
Killer whales: orcas blow fish to bits 'for fun', study finds
-
Houthis target Red Sea shipping as US hits Iran
-
Deadly wildfires force thousands from homes in parts of Europe
-
Record-equalling Red Sox streak halted at 15 wins
-
Tech bounce lifts Asia stocks, oil extends gains on US-Iran fears
-
Messi-less Miami beat Fire 3-2 to spoil Lewandowski's MLS debut
-
Surrounded by militias, Sudanese fear endless cycle of war
-
Mercedes expect Hungary challenge from Hamilton and Ferrari
-
Commonwealth Games 'where champions are made' despite slimmed down model, argues president
-
In Ghana, one man's race to save critically endangered fish
-
Trump family project in Albania has already caused 'irreparable' damage: NGOs
-
Wilson captain, Slipper absent in Kiss's first Wallabies squad
-
Bollywood blast master keeps it real with fire and fury
-
New Mideast fighting puts eurozone rate-setters on alert
-
Tearful fights, edible offerings: A glimpse into the Maradona trial
-
Venezuelans search for animal companions lost in the quakes
-
What's the deal with peptides? The hyped market under US review
-
Argentine Football Association says US did not detain its president
-
Tesla shares fall as Musk touts ambitious -- and costly -- plans
-
June heatwave cost UK economy more than £1bn: study
-
Houthis claim Red Sea tanker strikes as US hits Iran again
-
Google-parent Alphabet beats expectations, cloud revenue nearly doubles
-
Wildfires ravage parts of southern France, Italy and Spain
-
US announces civilian nuclear deal with Saudi Arabia
-
Alphabet beats expectations in second quarter, cloud revenue nearly doubles
-
Tesla shares dip after profit misses expectations
-
Trump threatens Iran infrastructure, Tehran vows 'eye for eye'
-
Red Sox tie club record with 15th straight MLB win
-
US teen withdraws lawsuit against Meta over social media addiction
-
US eyes offshore nuclear reactors
-
Lebanon PM says Beirut working for 'complete Israeli withdrawal'
-
The Sterling Announces Luxury Cocktail Lounge Concept and Investor Showcase in Orlando
-
EU conditionally clears Paramount bid for Warner Bros.
-
Inter Miami signs Brazil veteran Casemiro but MLS probes deal
-
Philipsen snaps 'horrible' drought with Tour de France stage 17 victory
-
White House accuses China's Moonshot of stealing Anthropic AI
-
US trial of Venezuela's Maduro set for June 2027
-
Pogacar sweating on Yates's fitness ahead of Tour Queen stage
-
New UK PM Burnham gets early boost as inflation dips
-
Ukrainian soldiers and civilians welcome new army commander
-
Samsung launches new, more expensive foldable smartphones
-
UK fintech Revolut valuation soars to $115 bn: source
-
Philipsen ends 'horrible' drought with Tour de France 17th stage victory
Ozempic slimming craze sweeps Kosovo despite side effects
Kosovo influencer Tringa Kadriu sees the slimming drug Ozempic as a chance to shed excess pounds -- and she is not the only one in her Balkan nation, where more than half the population is overweight.
"I want to lose 15-16 kilos (33-35 pounds) in two months," Kadriu, 29, told AFP, "and then I'll continue with fitness".
Ozempic, approved in the United States to treat diabetes in 2017, has found an international market for people trying to lose weight.
Despite its cost, the drug has soared in popularity in Kosovo, a country of 1.7 million.
While Kosovo authorities have not sanctioned the drug's use for weight loss, they have noted their limited means to confront use of a drug widely available in the country.
Merita Emini-Sadiku, who heads the Kosovo university hospital's endocrinology clinic, said the cost of the drug had soared.
"The monthly dose used to be 75-80 euros ($85-91), while now it is 130-140 euros ($147-159), probably due to high demand," she said.
But she warned that "Ozempic has side effects that people are not aware of".
Ozempic use can potentially cause issues including thyroid cancer, pancreatitis, gastroparesis and bowel obstruction, according to the latest studies.
- 'Constant demand' -
Meant to treat Type 2 diabetes -- of which the WHO says Kosovo has lower than average levels -- the drug regulates blood sugar levels but also helps suppress hunger, leading to a lower calorie intake.
As a result, its potentially cancerous complications have done little to stem the drug's popularity or availability.
"I checked a lot of pharmacies in Kosovo and I noticed that Ozempic is very easy to get," said Kadriu, adding that pharmacists even suggested she gradually increase her dosage.
A worker at a pharmacy in the capital Pristina's downtown, who asked to remain anonymous, said she had trouble recalling when someone last came into her pharmacy to buy Ozempic with a diabetes prescription.
"But we have a constant demand for Ozempic without a prescription. You can guess why," she said.
Given its availability, Emini-Sadiku said authorities should exercise greater control over Ozempic's distribution.
But Bujar Vitija, a journalist specialising in health, said that would be tricky to achieve given Kosovo's poor health record-keeping.
"Unfortunately there is no data," Vitija said.
With 1,500 to 1,600 private pharmacies in Kosovo, the country's 20 pharmaceutical inspectors have their work cut out for them, he added.
- Ozempic 'every day' -
While Kosovo has lower levels of obesity than the European average, more than 57 percent of the population is overweight and 20 percent is clinically obese, according to a 2019 World Health Organization report.
And women, who are more likely to face societal pressure to be thin, were 66 percent more likely to be obese than men, the WHO report found.
But not every Kosovar who has used Ozempic had the best experience with the drug.
"I took Ozempic on the advice of a doctor for two years but it had no effect," said 48-year-old merchant Lulzim Rrahmani, adding that three of his relatives even experienced "a negative effect of the drug".
"It was just a waste of money and time."
Given the risk of side effects, Emini-Sadiku said Ozempic was "by no means to be taken without a doctor's prescription".
Yet Kadriu said she would not be deterred, adding that she saw colleagues taking the drug "every day at work".
"I don't see any symptom that would deter me."
N.Schaad--VB